化合物TZ9 T17187

Product Introduction
Bioactivity


英文名: TZ9

描述: TZ9 是一种具有选择性和有效性的 Rad6 抑制剂，具有抗癌和而抗肿瘤活性。TZ9 对 Rad6B 诱导的组蛋白 H2A 泛素化有抑制作用。TZ9 诱导细胞周期停滞和细胞凋亡。

体外活性: In MDA-MB-231 cells, TZ9 (Rad6B SMI #9) inhibits proliferation and migration when administered at concentrations ranging from 0.5 to 100 µM for 72 hours[1].Cell-cycle progression delay is observed in MDA-MB-231 cells treated with TZ9 at concentrations ranging from 0.1 to 5 µM over a period of 24 to 72 hours[1].Apoptosis induction is noted in MDA-MB-231 cells exposed to TZ9 at a concentration of 5 µM for 8 to 48 hours[1].In MDA-MB-231 cells, TZ9 exhibits inhibitory effects on H2A ubiquitination and downregulates levels of PCNA and β-catenin protein when applied at concentrations of 0.5, 1, 2.5, and 5 µM for 24 hours[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 40 mg/mL (109.19 mM)


关键字: TZ-9 | TZ 9 | TZ9

相关产品: Chelerythrine | 4-Thiothymidine | Lacidipine | icFSP1 | Ginsenoside Rg1 | Nebularine | PYR-41 | Dihydrokaempferol | Deferasirox (Fe3+ chelate) | RGD peptide (GRGDNP)

相关库: Inhibitor Library

化合物TZ9 T17187信息由TargetMol中国为您提供，如您想了解更多关于化合物TZ9 T17187报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途